Cellmid options cancer diagnostics tech
Cellmid (ASX:CDY) has secured an option agreement with Japan’s Fujikura covering its midkine cancer diagnostics technology in latex-based tests.
Japan’s Fujikura Kasel, a supplier of latex particles for the medical diagnostics industry, will evaluate incorporating Cellmid’s (ASX:CDY) anti-midkine diagnostic antibodies into its latex platform.
Under the agreement, Cellmid will be entitled to an initial fee as well as a further payment and royalties on future sales if the Japanese company exercises its option to license the technology.
The licence option is contingent on Fujikura achieving a limit of detection of at least 500 picogram/mL of midkine in serum on its latex diagnostics platform.
Most healthy people have midkine levels below this threshold, so a test with this limit of detection could be used to develop new cancer diagnostics products.
Announcing the deal, Celmid said its Midkine ELISA assay can detect midkine to a limit of 8 picogram/mL and that Fujikura aims to achieve a similar sensitivity on its latex platform.
Midkine serves as an early marker for a range of cancers and also has potential applications in prognosis and disease management.
Fujikura head of medical projects Dr Hideyuki Kuroda said a midkine diagnostics platform “lends itself to multiple, high-value product development opportunities”.
Besides commercialising midkine as a biomarker for cancer diagnostics, Cellmid is researching using its proprietary anti-midkine antibodies as a treatment for cancers, as well as diseases including diabetic nephropathy.
Cellmid (ASX:CDY) shares were trading unchanged at 2.2c as of around 1 pm on Monday.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...